Belapectin

Last updated
Belapectin
Clinical data
Other names
  • GR-MD-02
  • Galactoarabino-rhamnogalacturonate
Legal status
Legal status
  • Investigational
Identifiers
  • α-D-Galacturono-α-D-galacto-β-D-galacto-6-deoxy-α-L- manno-α-L-arabinan, (1→2),(1→3),(1→4)-, methyl ester
CAS Number
DrugBank
UNII

Belapectin (also known as GR-MD-02) is a galectin-3 inhibitor developed by Galectin Therapeutics for the treatment of non-alcoholic steatohepatitis. [1] [2] [3] [4] In a phase 2b/3 trial belapectin at 2 mg/kg/LBW reduces varices development in MASH cirrhosis with portal hypertension. [5]

References

  1. ↑ Al Attar, Atef; Antaramian, Ani; Noureddin, Mazen (3 April 2021). "Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis". Expert Review of Clinical Pharmacology. 14 (4): 457–464. doi:10.1080/17512433.2021.1894127. PMID   33612037.
  2. ↑ Kram, Michael (Feb 27, 2023). "Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis". World J Hepatol. 15 (2): 201–207. doi: 10.4254/wjh.v15.i2.201 . PMC   10011901 . PMID   36926236.
  3. ↑ Slack, R.J.; Mills, R.; Mackinnon, A.C. (January 2021). "The therapeutic potential of galectin-3 inhibition in fibrotic disease". The International Journal of Biochemistry & Cell Biology. 130 105881. doi: 10.1016/j.biocel.2020.105881 . PMID   33181315.
  4. ↑ Tapper, Elliot B.; Ufere, Nneka N.; Huang, Daniel Q.; Loomba, Rohit (May 2022). "Review article: current and emerging therapies for the management of cirrhosis and its complications". Alimentary Pharmacology & Therapeutics. 55 (9): 1099–1115. doi:10.1111/apt.16831. ISSN   0269-2813. PMC   9314053 . PMID   35235219.
  5. ↑ "Belapectin at 2 mg/kg/LBW reduces varices development in MASH cirrhosis with portal hypertension: results from the NAVIGATE trial" (PDF). EASL Congress. 2025. 10 May 2025.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.